



Nicox's Ordinary Shareholder Meeting

April 29, 2016

Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, has convened an ordinary shareholder meeting on **Tuesday June 7, 2016 at 2:00 pm CET** at BuroClub – room Colomb – Drakkar 2 - Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis - France.

The documents mentioned in articles L.225-115, R. 225-81 and R. 225-83 of the French Code de commerce, including a proxy voting form, will be sent to shareholders upon written request. These documents will also be made available to shareholders at the headquarters and on the website of the Company (www.nicox.com) by May 17, 2016.

Shareholders may vote by proxy or by attending the shareholder meeting in person. A guide explaining how to vote will be posted on Nicox's website by May 17, 2016. Shareholders may also contact the Company's Investor Relations team at communications@nicox.com for any question on the voting process.

In the event the quorum is not reached on the first call, Nicox will convene a shareholder meeting on a second call on Tuesday June 21, 2016 at 2:00 pm CET at BuroClub – room Colomb – Drakkar 2 - Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, Nicox is building a diversified portfolio of ophthalmic products that can help people enhance their sight.

Nicox's advanced pipeline features latanoprostene bunod for the lowering of intra-ocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, and for which a New Drug Application (NDA) was submitted to the FDA by the Company's licensee Bausch + Lomb, Valeant Pharmaceuticals International, Inc.'s, wholly owned subsidiary. The Company's pipeline also features AC-170, for which the NDA was submitted to the FDA for the treatment of ocular itching associated with allergic conjunctivitis in April 2016, as well as two pre-MAA candidates in Europe: AzaSite[®] for bacterial conjunctivitis and BromSite[™] for pain and inflammation after cataract surgery. Beyond these late-stage candidates, Nicox is developing a pipeline of next generation ophthalmology-focused candidates which utilize its proprietary nitric oxide (NO)-donating research platform. The Group has operations in Europe and the United States.

Nicox is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its commercial products or pipeline, please visit www.nicox.com.

Analyst coverage

| | | |
|---|---|---|
| Bryan, Gamier & Co Invest Securities Gilbert Dupont | Hugo Solvet Martial Descoutures Damien Choplain | Paris, France Paris, France Paris, France |
|---|---|---|



Contacts

Nicox

Gavin Spencer | Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00 | communications@nicox.com

This press release contains certain forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the '*Document de référence, rapport financier annuel et rapport de gestion 2015*' filed with the French *Autorité des Marchés Financiers* (AMF) on April 15, 2016, which is available on Nicox's website (www.nicox.com).